Billiontoone (NASDAQ:BLLN) Insider Sells $287,363.04 in Stock

by · The Cerbat Gem

Billiontoone, Inc. (NASDAQ:BLLN – Get Free Report) insider Bosch John Roderick Ten sold 2,832 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $101.47, for a total value of $287,363.04. Following the transaction, the insider owned 34,968 shares of the company’s stock, valued at $3,548,202.96. This represents a 7.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Billiontoone Price Performance

NASDAQ BLLN traded down $1.32 during trading on Wednesday, hitting $99.38. 963,691 shares of the stock traded hands, compared to its average volume of 453,406. The firm has a 50-day simple moving average of $88.95 and a 200-day simple moving average of $87.60. Billiontoone, Inc. has a 12-month low of $61.96 and a 12-month high of $138.70. The company has a quick ratio of 10.58, a current ratio of 10.92 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $4.57 billion and a P/E ratio of 180.69.

Billiontoone (NASDAQ:BLLN – Get Free Report) last posted its earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.33. The business had revenue of $108.39 million during the quarter, compared to analysts’ expectations of $95.81 million. During the same period last year, the business posted ($0.39) earnings per share. The company’s revenue for the quarter was up 83.8% compared to the same quarter last year. As a group, analysts predict that Billiontoone, Inc. will post 0.93 EPS for the current year.

Hedge Funds Weigh In On Billiontoone

Large investors have recently added to or reduced their stakes in the company. Rossby Financial LCC purchased a new position in shares of Billiontoone during the 4th quarter valued at about $25,000. Wells Fargo & Company MN acquired a new stake in shares of Billiontoone in the fourth quarter worth approximately $76,000. Smartleaf Asset Management LLC acquired a new stake in Billiontoone during the 4th quarter worth $80,000. Nano Cap New Millennium Growth Fund L P acquired a new stake in Billiontoone during the 4th quarter worth $82,000. Finally, Renaissance Capital LLC acquired a new stake in Billiontoone during the 4th quarter worth $201,000.

Analysts Set New Price Targets

Several research firms have commented on BLLN. JPMorgan Chase & Co. lifted their price objective on shares of Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Wall Street Zen upgraded shares of Billiontoone from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Weiss Ratings lowered shares of Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 5th. Guggenheim boosted their target price on Billiontoone from $100.00 to $120.00 and gave the company a “buy” rating in a research report on Wednesday, May 13th. Finally, Wells Fargo & Company cut their target price on Billiontoone from $110.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 5th. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $125.29.

Check Out Our Latest Analysis on Billiontoone

Billiontoone Company Profile

(Get Free Report)

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.

Featured Articles